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Targeted therapy in patients with radioiodine-refractory 
differentiated thyroid cancer (DTC)
Abstract
Papillary (PTC) and follicular (FTC) thyroid cancer (TC) belong to 
differentiated thyroid cancer (DTC). The initial treatment of DTC is sur-
gery followed by radioiodine remnant ablation. Although the prognosis of 
DTC is generally good, approximately 10-15% of DTC patients will devolp 
advanced disease and their disease will become radioiodine refractory. Even 
in radioiodine refractory patients the natural history of disease can be slow-
ly progressive or indolent.The expanded knowledge of the the biological 
basis of DTC has opened new opportunities in therapy – targeted therapy, 
aimed at inhibiting specific molecular targets and pathways in tumor pro-
liferation, survival and progression. We rewieved different tageted therapies 
in DTC. Sorafenib was the first and only targeted drug approved by FDA 
for progressive and radiodine-refractory DTC. Also, lenvatinib had prom-
ising efficacy results in phase III trial, probably even better than sorafenib, 
but with more treatment-related deaths.
The timing of targeted therapy for DTC is of decisive importance. The 




The incidence of thyroid cancer (TC) has been globally increasing over the last 30 years. This is attributed to an increase of diagnosing 
of small tumors (<2cm) by using high-frequency ultrasound probes and 
fine-needle aspiration (FNA) biopsies, and due to increased enviromen-
tal and medical radiation exposure, increased iodine intake, ethnic and 
genetic factors (1). According to Croatian National Cancer Registry, 
452 new thyroid cancers were diagnosed in 2011 (2). Despite such a trend 
in incidence, the mortality, in western countries, has remained stable 
or is slowly decreasing (3). Thyroid cancers are divided into four major 
histological types: papillary (85%), follicular (11%), medullary (35%), 
and anaplastic (1%). Papillary (PTC) and follicular thyroid cancer 
(FTC) are referred to as differentiated thyroid cancers (DTC). In gen-
eral, 5-year survival rate of DTCs is more than 97% (4). Tumors mea-
suring less than 1 cm (thyroid microcarcinomas) have an excellent prog-
nosis with 10-15 years disease-specific survival rates exceeding 99% (5). 
Despite the general good prognosis of well differentiated TCs, some of 
them will develop a metastatic disease and cause a bad outcome. This 
has precluded the development of large body of trials to determine how 
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chimeric oncogene with a protein product containing a 
constitutively activated RET tyrosine kinase. At least 10 
types of RET/PTC rearrangement have been identified. 
RET/PTC rearrangements are common in small, multi-
focal PTCs accompanied by an inflammatory infiltrates 
and are often seen in patients exposed to ionizing radia-
tion (for example 70% of cancers found in Chernobyl 
survivors carried a RET/PTC rearrangement).
Another chromosomal translocation occurs in FTCs. 
The promoter region of the gene, encoding paired box 8 
(PAX8) fuses with the coding sequence of the peroxisome 
proliferator-activated receptor-g (PPARg), was found in 
35% of FTCs.
Most of the genetic alterations in thyroid cancer exert 
their oncogenic actions at least partially through the ac-
tivation of the RET/PTC-RAS-RAF-MEK-ERK mito-
gen-activated protein kinase (MAP kinase) pathway.
Activation of this pathway is a common and important 
mechanism in the genesis and progression of human can-
cers through upregulating cell division and proliferation. 
When constitutively activated, the MAP kinase pathway 
leads to tumorigenesis. BRAF-activating missense point 
mutations in the kinase domain are clustered in exons 11 
and 15 of the gene and the T1799A transversion mutation 
accounts for more than 80% of all the BRAF mutations. 
The T1799A mutation results in a V600E amino acid 
substitution in the protein product and subsequent con-
stitutive activation of the BRAF kinase.
BRAF mutation is the most common genetic alteration 
in thyroid cancer, occurring in about 45% of PTCs, par-
ticularly in the relatively aggressive subtypes, such as the 
tall-cell PTC. BRAF mutation is mutually exclusive with 
RET/PTC rearrangement. This mutation is associated 
with a poorer clinicopathological outcome and is a novel 
independent molecular prognostic marker in the risk 
evaluation of thyroid cancer (11).
patient characteristics and modalities of treatment affect 
the cause-specific mortality.
In addition to tumor size; age, completeness of resec-
tion, extrathyroidal extension, multicentricity, tumor 
grades are also prognostic factors that are used in many 
prognostic score systems for DTC. Prognostic scores 
caterogise patients into low-risk and high-risk groups 
based on stated variables (6). The regional lymph node 
involment in determing DTC- specific survival remains 
controversial. Historically, the presence of lymph node 
metastases was belived to increase the reccurence without 
affecting survival, therefore the rutine lymph node dis-
section is often avoided. Large series and population-
based studies suggest that lymph node involvement pro-
duces small but significant effect on survival (7).
It is very important to recognise more agressive vari-
ants of DTCs such as tall-cell, columnar- cell, and dif-
fuse-sclerosing subtype of DTC. Anaplastic thyroid can-
cers (ATC) are the least-differentiated and the most 
aggresive cancers of all. According to differentiation and 
prognosis, poorly differentiated thyroid cancers fall be-
tween the group of DTCs and ATCs. These tumors are 
insular and large-cell variants (8). Pure FTC carries a 
worse prognosis in comparison to PTC. Mortality rate 
ranges from 5 to 15%, although survival extends as in 
PTC (9). Hürthle cell or oncocytic tumor of thyroid ar-
rises from the follicular epithelium and carries a worse 
prognosis compared with other DTCs (10).
Recently, the data on genetic etiology of DTC has seen 
abundant growth (see Figure 1). Investigations into ac-
quired genetic lesions that can distinguish carcinoma 
from benign thyroid nodule increased in the last decade. 
One of such markers is RET/PTC rearrangement. RET/
PTC rearrangement represents a recombination of the 
promoter and N-terminal domain of a partner gene with 
the C-terminal region of the RET gene, resulting in a 
Figure 1. Genetic etiology of thyroid cancer.
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that there was no significant difference between the low 
and high dose regimen (19). Recommended doses are 
(1100 to 3700 MBq or 30 to 100 mCi) for patients with 
lower risk and higher doses (3700 to 7400 MBq or 100 to 
200 mCi) for patients with residual disease and more ag-
gressive histological subtypes. Effective RAI requires the 
TSH concentrations at least as high as 30 mU/l to stimu-
late targeted (intracellular) uptake of I-131. The method 
of choice according to ESMO Clinical Recommendations 
for preparation for RAI is based on the administration of 
recombinant human TSH (rhTSH) while the patient is 
on levo-thyroxine (LT4) therapy. The traditional method 
is the withdrawal from thyroid replacement therapy (LT4) 
over 4-6 weeks to produce profound hypothyroidism.
Thyroxine suppression is another adjuvant approach in 
therapy of DTCs. TSH suppression is provided through 
the administration of supraphysiological doses of LT4. 
For high-risk patients LT4 doses should be initially ti-
trated to a TSH of less than 0.1 mU/l, and for lower- risk 
patients between 0.1 to 0.5 mU/l. After few years of fol-
low-up and in the absence of TC recurrence, TSH values 
can be returned to reference ranges (12).
conventional therapy for recurrent 
locoregional and metastatic tc
The most common sites of distant metastases from 
DTC are the lungs (50%) and bone (25%), followed by 
the brain, liver, kidneys, and muscles (5%). Two-thirds 
of patients who develop locoregional recurrence and one-
third with distant metastases may achieve complete re-
mission. Older patients have the worst prognosis (>45 
years old) with metastatic disease. These patients have a 
5-year survival rate of only ~30% to 40% (20). Aggressive 
surgery, radioiodine therapy, and levothyroxine suppres-
sion therapy can improve overall survival and disease-
specific survival in this subgroup of patients.
Treatment of locoregional recurrence is based on the 
combination of surgery and RAI.
External beam radiotherapy is reserved as an option, 
if surgery and RAI have been exhausted. Chemotherapy 
has not been largely evaluated for metastatic DTCs, but 
it is known to confer minimal effects (responses from 0% 
to 22% with the most used agent, doxorubicin) (21).
In approximately 5%-15% of patients with thyroid 
cancer, the disease becomes refractory to RAI (22). Re-
sistance to RAI is defined by the presence of at least one 
tumor focus without any iodine uptake, by progression 
of the disease after RAI, and in patients with persistent 
disease after administration of cumulative dose of 600 
mCi I-131 (see figure 2). RAI refractory disease occurs 
more often in older patients, in those with large metasta-
ses and those with positive FDG-PET scans. Median 
survival for patients with RAI-refractory DTC and dis-
tant metastases is estimated to be 2.5 - 3.5 years (23).
The Ras proteins are plasma membrane GTPases acti-
vated by growth factor receptors. Mutations that result in 
constitutive activation of RAS lead to tumorogenesis. 
RAS mutations occur in 20% to 50% of follicular cancers 
(12).
Initial treatment of differentiated 
thyroid cancer
The initial therapy of DTC should always be preceded 
by ultrasound exploration of the neck to access the neck 
lymph node status. The initial treatment for DTC is total 
or near-total thyroidectomy. Based on clinical recom-
mendations (ESMO-European Society for Medical On-
cology) and NCCN (Nation Comprehensive Cancer 
Network), the total thyroidectomy is surgical procedure 
of choice whenever the diagnosis is known before surgery 
(in most cases by FNA biopsy) and the thyroid nodule is 
1 cm. The extent of thyroidectomy could be individual-
ized for lower-risk PTC, but despite of clinical practice of 
some centers, the thyroid lobectomy is still a controversial 
issue. There are no randomized prospective trials compar-
ing total thyroidectomy with thyroid lobectomy in low-
risk TCs. Furthermore, radioactive iodine therapy for 
ablating microscopic disease becomes most effective when 
total thyroidectomy was performed or when small 
amount of thyroid remnant tissue is present. Multicentric 
tumors, with lower risk of recurrence in cervical lymph 
nodes, as well as easier long-term follow-up with thyro-
globulin (Tg) determinations and whole-body 131-I im-
aging provide additional arguments for total thyroidec-
tomy. The benefit of prophylactic central node dissection 
(level VI lymph nodes that include paratracheal, perithy-
roidal and precricoid lymph nodes) is another controver-
sial topic related to the extent of initial surgery for DTC. 
Several studies support the concept that prophylactic cen-
tral neck dissection is not necessary in case of postopera-
tive radioactive iodine (RAI) ablation (13, 14, 15).
Radiodine therapy (I-131) therapy is the standard ad-
juvant treatment after a total or near-total thyroidectomy 
aimed to ablate remnant thyroid tissue and microscopic 
residual disease. It is the first targeted therapy in onco-
logical history and this procedure decreases the risk of 
locoregional recurrence (IA level of evidence according 
to ESMO Clinical Recommendations). As with the con-
troversy over the extent of thyroidectomy, the benefit of 
RAI for low-risk patients remains unclear. There is no 
indication for RAI in very low-risk patients (those with 
unifocal T1 tumors, 1 cm in size, with favorable histol-
ogy, no extrathyroidal extension or lymph node metasta-
ses). Some studies have shown an increase in the risk of 
developing secondary malignancies after RAI (hemato-
logical malignancies are the most common) (16). Two 
large prospective trials (the ESTIMABL study and the 
HiLo trial) were performed to compare different activities 
for RAI ablation in patients with DTC (17, 18). A meta-
analysis including previously mentioned trials showed 
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However, metastatic DTC can be asymptomatically 
stable for long period of time. Progression rate of meta-
static disease can be assessed by the doubling time of thy-
roglobulin and confirmed with morphological diagnostic 
methods (22).
tArGEtEd tHErAPY For 
dIFFErEntIAtEd tHYroId cAncEr
SORAFENIB is a small molecule that inhibits all Raf 
kinases (A-Raf, B-Raf and C-Raf),
Additionally, it targets a panel of angiogenic tyrosine 
kinase receptors such as vascular endothelial growth factor 
receptors (VEGFR 1-3), platelet-derived growth factor 
receptor b(PDGFRb) and RET.
Since 2006, larger number of clinical studies has been 
conducted with sorafenib (Table 1), mostly phase II, but 
a Phase III study has recently been published, which re-
sulted in that the US Food and Drug Administration 
(FDA) approved sorafenib for the treatment of RAI resis-
tant metastatic DTC. The studies varied in the subtypes 
of DTCs that were included. All the studies have the 
unique peroral dose of sorafenib 400 mg/bid. Brose et al. 
(37) published randomized, double-blind, placebo-con-
 
 
Figure 2. Shows radioiodine refractory metastases in patient with 
DTC; negative I-131 scan (image at the top) and intense fluorode-
oxyglucose (FDG) uptake in lung metastases (PET-CT scan at the 
bottom).
Targeted therapy in patients with radioiodine-refractory D. Herceg and Gordana Horvatić Herceg
Period biol, Vol 116, No 4, 2014. 403
trolled phase III trial (DECISION), which comprised 417 
patients. Patients assigned to the placebo group whose 
disease progressed during the trial could „cross over“ and 
receive sorafenib. Median progression-free survival was 
significantly longer in the sorafenib group (10.8 months) 
than in the placebo group (5.8 months); hazard ratio (HR) 
0.59. The objective response rate (ORR) was 24% in the 
sorafenib group and less than 1% in the placebo group. 
Overall survival (OS) did not differ between the patients 
treated with sorafenib and those who received a placebo. 
Stable disease (SD) 6 months in the sorafenib group was 
41.8%. Among the patients with no objective response, 
nearly 42% in the sorafenib group had stable disease for 
at least 6 months after beginning the treatment, compared 
with 33.2% of those in the placebo group. Disease control 
rate (complete remission CR+ partial remission PR+SD) 
was significantly better for the sorafenib group in com-
parison to the placebo group (P<0.0001). Information on 
BRAF and RAS mutations in the patients’ tumor tissue 
was available for 61% of all patients in the trial (126 pa-
tients in the sorafenib group and 130 patients in the pla-
cebo group). Mutations in these genes were not associated 
with longer progression-free survival in patients treated 
with sorafenib. The side effects were mainly low-grade and 
included hand-foot reaction, skin rash, fatigue, and hair 
loss. Nevertheless, nearly two-thirds of patients in the 
sorafenib group had their treatment temporarily halted or 
the drug dose reduced, and nearly 19% stopped the treat-
ment altogether because of side effects. Approximately 
37% of the patients in the sorafenib group and 26% of the 
patients in the placebo group had a serious adverse event 
(SAE). SAE in the sorafenib group included the develop-
ment of a second primary cancer, breathing difficulties, 
and pleural effusion. One death, caused by a heart attack, 
was also attributed to sorafenib. The toxicity profile is ac-
ceptable and it is similar to the toxicity profile in hepato-
cellular carcinoma.
LENVATINIB is a synthetic, orally available inhibitor 
of VEGFR1-3 tyrosine kinase, fibroblast growth factor 
receptor (FGFR 1-4), PDGFRb, RET and KIT resulting 
in inhibition of the VEGF receptor signal transduction 
pathway, resulting in decrease of vascular endothelial cell 
migration and proliferation, and vascular endothelial cell 
apoptosis. Lenvatinib showed promising results in thyroid 
cancer in Phase I (38). In phase II trial (39) lenvatinib 
induced a PR in 45% of 58 patients and SD in another 
46% of patients. Median PFS was 13.3 months. In SE-
LECT (40), global, randomized, double-blind, placebo-
controlled phase III study 392 patients were enrolled. 
Upon progression, the patients receiving placebo could 
crossover to open-label lenvatinib. In the patients with 
RAI resistant DTC, lenvatinib significantly prolonged the 
median PFS by 14 months compared with placebo (len-
vatinib median PFS: 18.3 months (95% CI 15.1-NR), the 
placebo median PFS (95% CI 2.2-3.7); HR 0.21 (99% CI, 
0.14-0.31)). Response rate for lenvatinib and placebo, re-
spectively, were: ORR: 65% vs 2% (with CR; 2% vs 0%). 
The median time to objective response to lenvatinib was 
2.0 months (95% CI, 1.9-3.5 months). The median dura-
tion of response for lenvatinib has not been reached, but 
75% of responders had an objective response >9.4 months. 
Median OS has not been reached. The 5 most common 
lenvatinib treatment-related adverse events of any grade 
were hypertension (68%), diarrhea (59%), appetite de-
creased (50%), weight loss (46%), nausea (41%). Lenva-
tinib grade 3 treatment-related adverse events (5%) 
were hypertension (42%), proteinuria (10%), weight loss 
(10%), diarrhea (8%), appetite decreased (5%). 6 of 20 
lenvatinib treatment-emergent deaths were considered as 
treatment-related: pulmonary embolism (n=1), hemor-
rhagic stroke (n=1), general health deterioration (n=4).
VANDETANIB targets epidermal growth factor re-
ceptor (EGFR), VEGFR2 and 3, RET kinases. Based on 
ZETA (phase II/III randomized placebo-controlled trial) 
FDA approved vandetanib for the treatment of symptom-
atic or progressive medullary thyroid cancer (MTC) in 
patients with unresectable, locally advanced or metastatic 
disease. Potentially serious cardiac effects (QT prolonga-
tion, torsades de pointes and sudden death) call for caution 
in prescribing this medication (41).
Improved PFS has been reported in a double-blind 
phase II study, where 45 patients with metastatic or lo-
cally advanced DTC were enrolled. The results showed 
longer PFS in the vandetanib group (11.1 months) with 
respect to the placebo group (5.9 months). The safety in 
this study was similar to previous studies of vandetanib 
(42).
MOTESANIB is a highly selective inhibitor of PDG-
FR, VEGFR 1-3 and c-KIT and inhibits cellular prolif-
eration and angiogenesis. Trial II was conducted in pa-
tients with advanced RAI resistant DTC on motesanib 
phase (43). Median PFS of 40 weeks was achieved. Most 
common treatment-related adverse events were hyperten-
sion (56%), diarrhea (59%), fatigue (46%) and weight loss 
(40%).
AXATINIB targets PDGFR, VEGFR 1-3 and c-KIT. 
It is considered the most potent VEGFR2 inhibitor. In 
clinical studies patients suffering from DTC and MTC 
were randomized. PR was shown in 30% (18) patients and 
SD in 38% (23) patients. The most common adverse event 
was hypertension. In 3 patients grade 4 toxicity was diag-
nosed caused by hypertension, stroke and reversible pos-
terior leukoencephalopathy (44).
SUNITINIB targets c-KIT, VEGFR-2, PDGFR, 
RET. Phase II study of sunitinib was conducted in refrac-
tory TC. The best response was PR 13% in 31 evaluable 
DTC patients, and SD 68%. The toxic profile was the 
same as seen in therapy of renal cancer (hypertension, 
thrombocytopenia, fatigue, neutropenia, palmar-plantar 
erythrodysestesia, and gastrointestinal symptoms (45). In 
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TABLE 1
Phase II studies of sorafenib for radioiodine resistant DTC.
studies Thyroid cancer type numbers Responses
Gupta-Abramson (24) 30 DTC PR 23%, SD 53%, mPFS 79 weeks
Brose (25)
29 PTC, 18 FTC, 3 MTC, % 
PD/anaplastic
mPFS 84 weeks (DTC)
Kloos (26) 52 DTC/4 ATC PR 15%, SD 56% (PTC), FTC no reponse, mPFS 15 months
Hoftijzer (27) 31 DTC PR 25%, SD 34%
Ahmed (28) MTC, DTC PR 16%, SD 68%
Cepdevilla (29) 15 DTC, 12 MTC, 3 ATC PR 19%, SD 50%, PFS 13.3 months, OS 23.6 months
Keefe (30) 47 DTC, 3 MTC, 5 ATC PR 38%, SD 47%, PFS 96 weeks, OS 140.9 weeks
Schneider (31) 31 DTC mPFS 18 months, mOS 34.5 months, PR 31%, SD 42%
Adili (32) 44 PD Sorafenih vs placebo mOS 34 vs 9 months, PR 23% vs12.5%, SD 62% vs 50%
Marotta (33) 17 DTC 30% PR, 41% SD
de la Fouchardiere (34) 45 DTC PR 29%, mPFS 6.7 months
Chen (35) 9 PTC PR 33%, SD 44%, mPFS 42 weeks
Cabanillas (36) 13 DTC 20% PD, mPFS 19 months
Abbreviations: DTC-differentiated thyroid cancer, PTC -papillary thyroid cancer, FTC -folicular thyroid cancer, ATC -anaplastic thyroid cancer, 
MTC – medullary thyroid cancer, PD – poorly differentiated thyroid canncer, PR – partial response, SD -stable disease, mPFS -mean progression free 
survival, mOS -mean overall survival
TABLE 2
Targeted therapy used in clinical trials in DTC.
drug tumor type study phase No of pts response PFS reference
lenvatinib DTC III 392 ORR 65% 18.3 vs 3.6 months 40
vandetanib DTC II 145 PR 1%SD 56% > 6 months 11.1 vs 5.9 months 42
motesanib DTC II 93 ORR 14% 40 weeks 43
axitinib DTC II 60 PR 30%SD 38% > 6 months 18 months 44
sunitinib DTC II 28 PR 29% 46
pazopanib DTC II 37 PR 49% 11.7 months 48
cabozatinib DTC I 15 PR 53%SD 66% >6 months 49
vemurafenib DTC II 51 PR 61%SD 66% >6 months 16 months 50
Abbreviations: DTC differentiated thyroid cancer; PFS progression free survival, ORR overall response rate, PR partial response, SD stable disease
the ASCO meeting 2008 THYSU study was presented 
with a small number of DTC patients, but the largest 
sunitinib phase II study published in 2010 enrolled 28 
patients with DTC. CR was shown in 1 patient, PR in 
28% and SD in 46% of patients (46).
CABOZATINIB is an oral inhibitor of multiple re-
ceptor tyrosine kinases including RET, MET, and VEG-
FR2. According to results of double-blind, randomized, 
placebo controlled phase III study (EXAM) FDA and 
EMA (European Medicines Agency) approved caboza-
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tinib for the treatment of progressive, metastatic MTC 
(47), but the data for cabozatinib in DTC patients are 
very limited. Only one phase I study with promising re-
sults was reported on the ASCO meeting 2011 (48).
PAZOPANIB is a small-molecule inhibitor of VEG-
FR 1-3, FGFR 1-3, PDGFR, interleukin-2 receptor in-
ducible T-cell kinase (Itk), leukocyte-specific protein 
kinase (Lck), c-Kit, and transmembrane glycoprotein re-
ceptor tyrosine kinase (c-Fms). In a Phase II trial, pazo-
panib induced a PR 49% of 37 patients and lasted more 
than one year for the patients with RAI- refractory met-
astatic DTC. Interestingly, pazopanib is frequently more 
effective in follicular and Hürthle cell cancer than in 
PTC. Dose reduction was required in 43% of patients 
because of adverse events such as fatigue, skin and hair 
hypopigmentation, diarrhea, nausea, hepatotoxicity and 
hypertension. SAE were QT prolongation, thromboem-
bolic events, and gastrointestinal perforation (49).
BrAF inhibitors
There are three kinds of Raf kinase proteins: A-Raf, 
B-Raf, and C-Raf. BRAF mutations results in signals for 
uncontrolled cellular proliferation. The most common is 
V600E mutation, in which valine is substituted with glu-
tamic acid, and it is found in 40-50% of PTC, melanoma, 
and colon cancer (11).
VEMURAFENIB is an orally administered BRAF 
V600E inhibitor, but also other BRAF mutations such as 
V600K, and V600R. Vemurafenib was the first BRAF 
inhibitor approved by FDA and EMA for metastatic 
melanoma. In the phase II trial, 51 patients with progres-
sive RAI refractory PTC were enrolled, and BRAF 
V600E mutation by cobas®4800 V600 Mutation Assay 
was confirmed. Patients were assigned to either cohort 1 
(TKI naive) or cohort 2 (if previously treated with TKIs). 
Median PFS was 15.6 months in cohort 1 and 6.8 months 
in cohort 2. The overall toxicity profile was consistent 
with that seen in melanoma trials. Common adverse 
events included rash, fatigue, weight loss and increased 
bilirubin (50).
DABRAFENIB is the second BRAF kinase inhibitor, 
also approved for metastatic melanoma. In a Phase I trial, 
patients with BRAF-mutant metastatic PTC had a 33% 
response rate (51).
The future direction would be to achieve a greater or 
durable response by utilizing combined targeted therapy. 
Sorafenib, as the first approved drug for progressive, RAI-
refractory thyroid cancer, was combined with other TKIs. 
In phase II prospective trial tipifarnib, a farnesyl trans-
ferase inhibitor was combined with sorafenib. The tipi-
farnib trials results in PR of 4.5%, while SD was seen in 
36% of DTC patients. Median PFS was 15 months, but 
the analysis included MTC participants. Sorafenib/tipi-
farnib toxicity was mostly grade 1-2, including rash, fa-
tigue, and diarrhea (52).
A sorafenib/temsirolimus (intravenous mTOR inhibi-
tor) showed 38% PR in the recurrent RAI-resistant DTC 
cohort that had not received previous systemic treatment 
(53). The same author reported a sorafenib/everolimus 
combination Phase II study with 28 RAI-resistant DTC 
of various histological subtypes and found PR between 
33% and 50%. Cumulative grade 4 toxicities were seen 
in the form of one case each of hyperglycemia, pancreati-
tis, and elevation of aminotransferases (54).
concLuSIon
In the vast majority of cases (90%) DTC is a curable 
disease. Even in metastatic setting, DTC has indolent, 
slowly progressive course, frequently cured by surgery, 
RAI and LT4 therapy. Two thirds of patients with metas-
tases have RAI-resistant disease and, until recently, there 
were no therapy options for them. The knowledge of the 
biological basis of thyroid cancer was sufficiently in-
creased, that induced the research on new targeted drugs, 
which aims to change the prognosis of patients with RAI-
resistant metastatic DTC. The shown data are based pri-
marily on Phase II trials, with only few on Phase III trials. 
We rewieved a wide variety of treatment strategies, but 
only sorafenib has been approved by FDA for progressive 
and RAI-refractory DTC so far. Also, lenvatinib had 
promising efficacy results in phase III trial, probably even 
better than sorafenib, but with more treatment-related 
deaths. For another rewieved drug, vandetanib, which 
was approved for MTC, the phase III trial for RAI- re-
fractory DTC (VERIFY study) is being conducted, and 
the results are expected.
If the natural course of metastatic DTC it is a slowly 
progressing disease, the risk of adverse events outweigting 
the potential benefit of new drugs. Therefore, the patients 
must show at least a progressive disease within one year 
before the initiation of targeted therapy. The initiation of 
systemic therapy for DTC patients should preferably be 
coordinated in referral centres and patients should, if pos-
sible, be enrolled in clinical studies.
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